Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy-Reference-Cited by-同舟云学术

Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy

Published:2011-02 Issue:2 Volume:22 Page:321-328
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Guiu S.,Liegard M.,Favier L.,van Praagh I.,Largillier R.,Weber B.,Coeffic D.,Moreau L.,Priou F.,Campone M.,Gligorov J.,Vanlemmens L.,Trillet-Lenoir V.,Arnould L.,Coudert B.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/22/2/321/409106/mdq397.pdf

Reference37 articles.

1. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis;Mauri;J Natl Cancer Inst,2005

2. Significance of histopathological evaluation in primary therapy for breast cancer—recent trends in primary modality with pathological complete response (pCR) as endpoint;Kurosumi;Breast Cancer,2004

3. Preoperative systemic (neoadjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial;Coudert;Ann Oncol,2006

4. Neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of a GETN(A) Group and OSMO Multicenter Phase II Trial (GETN[A]-1 trial) 547;Coudert;J Clin Oncol,2007

5. Amplification of a novel v-erbB-related gene in a human mammary carcinoma;King;Science,1985

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trastuzumab potentiates doxorubicin-induced cardiotoxicity via activating the NLRP3 inflammasome in vivo and in vitro;Biochemical Pharmacology;2023-08

2. Blood metabolomes as non-invasive biomarkers and targets of metabolic interventions for doxorubicin and trastuzumab-induced cardiotoxicity;Archives of Toxicology;2022-11-10

3. Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study;EClinicalMedicine;2020-11

4. Breast-conserving surgery in locally advanced breast cancer submitted to neoadjuvant chemotherapy. Safety and effectiveness based on ipsilateral breast tumor recurrence and long-term follow-up;Clinics;2017-03-04

5. HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy;PLOS ONE;2016-07-27